atogepant

Also Known As:

(3S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2-oxospiro(1H-pyrrolo(2,3-b)pyridine-3,6'-5,7-dihydrocyclopenta(b)pyridine)-3'-carboxamide

Networked: 51 relevant articles (14 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boinpally, Ramesh: 5 articles (06/2021 - 01/2020)
2.	Finnegan, Michelle: 4 articles (01/2022 - 01/2020)
3.	Trugman, Joel M: 4 articles (01/2022 - 01/2020)
4.	Goadsby, Peter J: 4 articles (01/2021 - 11/2019)
5.	Ailani, Jessica: 3 articles (01/2022 - 01/2020)
6.	Lipton, Richard B: 3 articles (01/2022 - 01/2021)
7.	Lu, Kaifeng: 3 articles (01/2022 - 01/2020)
8.	Miceli, Rosa: 3 articles (01/2022 - 01/2021)
9.	Severt, Lawrence: 3 articles (01/2022 - 01/2021)
10.	Butler, Matthew: 3 articles (06/2021 - 01/2021)

Related Diseases

1.	Migraine Disorders (Migraine) 04/01/2023 - "Atogepant appears to be beneficial for migraine prevention, and it may be more useful in those who do not want to take the medication as an injection or who do not require a lengthy duration of pharmacological impact. " 01/01/2023 - "Nominal improvements also occurred for other MSQ domains and HIT-6, reinforcing the beneficial effects of atogepant as a new treatment for migraine prevention. " 09/01/2022 - "The reduction in the mean number of migraine days from baseline across the 12-week treatment period was significantly greater among patients treated with atogepant at either the daily dose of 10 mg (MD - 1.16, 95% CI - 1.60 to - 0.73, p < 0.001), 30 mg (MD - 1.15, 95% CI - 1.54 to - 0.76, p < 0.001), or 60 mg (MD - 1.20, 95% CI - 2.18 to - 0.22, p = 0.016) than with placebo. " 04/01/2022 - "Atogepant seems to be beneficial for migraine prevention, and it may be of more benefit in individuals who do not wish to take the drug as an injection or do not require a prolonged duration of drug effect. " 09/01/2022 - "Atogepant is an efficacious and overall well-tolerated treatment for the prevention of episodic migraine in adults."
2.	Headache (Headaches) 01/01/2023 - "Over 52 weeks, atogepant 60 mg once-daily was associated with sustained improvements in quality of life and reductions in activity impairment and headache impact.Trial" 01/29/2022 - "It was found that atogepant (10 mg, 30 mg, 60 mg once a day) led to a significant reduction in monthly migraine days (P < 0.00001, P < 0.00001, P = 0.007), monthly headache days (P < 0.00001, P < 0.00001, P = 0.001), and monthly medication use days (P < 0.00001, P < 0.00001, P = 0.0001), and an increase in the proportion of people with ≥ 50% reduction in monthly migraine days (P = 0.0008, P = 0.02, P = 0.04) in comparison with placebo. " 01/01/2021 - "Oral atogepant once daily was effective in reducing the number of migraine days and headache days over a period of 12 weeks. " 01/01/2023 - "Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial." 04/01/2023 - "In terms of monthly migraine days, monthly headache days, and acute medication usage days, atogepant demonstrated a statistically significant difference from baseline. It was well-tolerated with low adverse event rates. "
3.	Prescription Drug Overuse 10/01/2023 - "Two randomized controlled trials (RCTs) have shown promising results for rimegepant and atogepant as preventive treatments for CM. In an RCT targeting patients with CM, atogepant demonstrated a significant reduction in the mean monthly migraine days, irrespective of acute medication overuse. "
4.	Nausea 01/01/2023 - "Most common adverse events for atogepant were constipation (30 mg twice a day 28 [10·9%]; 60 mg once a day 26 [10%]; and placebo 8 [3%]) and nausea (30 mg twice a day 20 [8%]; 60 mg once a day 25 [10%]; and placebo 9 [4%]). " 09/01/2022 - "Treatment with atogepant at the daily dose of 60 mg was associated with a higher risk of constipation (RR 4.92, 95% CI 1.89-12.79; p = 0.001) and nausea (RR 2.73, 95% CI 1.47-5.06; p = 0.001) than placebo. " 01/01/2021 - "The most common adverse events were constipation (6.9 to 7.7% across atogepant doses) and nausea (4.4 to 6.1% across atogepant doses). " 06/01/2021 - "The most commonly reported TEAEs were oropharyngeal pain (n = 2, with atogepant; not treatment related) and nausea (n = 2, with atogepant/acetaminophen; treatment related). "
5.	Pain (Aches) 06/01/2021 - "The most commonly reported TEAEs were oropharyngeal pain (n = 2, with atogepant; not treatment related) and nausea (n = 2, with atogepant/acetaminophen; treatment related). " 04/01/2023 - "Atogepant, the latest CGRP antagonist approved by the Food and Drug Administration (FDA) for prophylaxis of episodic migraine, works by non-competitively blocking CGRP receptors, thereby curtailing neurogenic inflammation and pain sensitization. " 01/01/2022 - "Atogepant is a 2nd-generation gepant that non-competitively antagonizes CGRP receptors inhibiting neurogenic inflammation and pain sensitization. "

Related Drugs and Biologics

1.	rimegepant sulfate
2.	fremanezumab
3.	eptinezumab
4.	galcanezumab
5.	erenumab
6.	Monoclonal Antibodies
7.	Calcitonin Gene-Related Peptide Receptor Antagonists
8.	ubrogepant
9.	Calcitonin Gene-Related Peptide
10.	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Oral Administration
4.	Duration of Therapy